Crizanlizumab receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered by multi-cell...
